Adage Capital Partners Gp, L.L.C. Bio Atla, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $1.52 Million - $3.8 Million	-1,196,148 Reduced 66.6%	600,000 $1.48 Million
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $167,949 - $303,297	-98,794 Reduced 5.21%	1,796,148 $3.05 Million
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $849,000 - $1.16 Million	300,000 Added 18.81%	1,894,942 $5.68 Million
Q1 2023 May 15, 2023	SELL	$2.3 - $8.25 $356,633 - $1.28 Million	-155,058 Reduced 8.86%	1,594,942 $4.27 Million
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $11 Million - $19.3 Million	1,750,000 New	1,750,000 $14.4 Million

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $16.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.